Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Summit Therapeutics PLC

SMMT
Current price
18.99 USD +0.02 USD (+0.11%)
Last closed 18.59 USD
ISIN US86627T1088
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 15 623 760 896 USD
Yield for 12 month +844.78 %
1Y
3Y
5Y
10Y
15Y
SMMT
21.11.2021 - 28.11.2021

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. Address: 601 Brickell Key Drive, Miami, FL, United States, 33131

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

28.25 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+704 295 USD

Current Quarter

Last Quarter

Current Year

-2 050 000 USD

Last Year

-1 809 705 USD

Current Quarter

-20 000 USD

Last Quarter

-27 000 USD

Key Figures SMMT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -143 592 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -31.01 %
PEG Ratio
Return On Equity TTM -102.77 %
Wall Street Target Price 28.25 USD
Revenue TTM
Book Value 0.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM 705 000 USD
Earnings per share -0.11 USD
Diluted Eps TTM -0.11 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics SMMT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History SMMT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:1
Payout Ratio
Last Split Date 21.09.2020
Dividend Date

Stock Valuation SMMT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6425.2766
Price Sales TTM 753.9008
Enterprise Value EBITDA -5.3247
Price Book MRQ 80.0911

Financials SMMT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators SMMT

For 52 weeks

1.64 USD 33.89 USD
50 Day MA 19.22 USD
Shares Short Prior Month 16 343 414
200 Day MA 9.21 USD
Short Ratio 2.68
Shares Short 15 446 534
Short Percent 13.29 %